Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Cancer Res. 2017 Dec 19;78(4):1044–1057. doi: 10.1158/0008-5472.CAN-17-1904

Figure 3. Absence of ufmylation pathway genes attenuates cell killing effect by THZ1 over erlotinib treatment.

Figure 3

A) Immunoblotting analysis of ufmyation pathway genes. B) Cell proliferation assay of PC9 cells transduced indicated sgRNAs. C) Umylation pathway depleted or control PC9 cells were treated with 50 nM THZ1 (THZ1), erlotinib (Erlotinib) or 50 nM THZ1 + erlotinib (Combo) for 18 days, (100 nM erlotinib was used for PC9 cells and 30 nM erlotinib was used for HCC827, respectively). The viable number of the cells was counted by Vi-cell counter at day 18 to quantify the cell proliferation. Each bar indicates the mean and SD of triplicate. D) Ufmylation depleted PC9 cells were pre-treated with 100 nM erlotinib for 48 hrs. Then treated by 100 nM THZ1. Cells were incubated with THZ1 for 96 hr. Each bar indicate mean ± SD. E) UFM1 or UFSP2 depleted HCC827 cells were treated as in C. F) UFM1 depleted HCC827 cells were treated as in D. G) Xenograft experiments with PC9 cells transduced indicated sgRNAs. Detailed experimental procedures described in Materials and Methods in Supplemental information.